PharmaPoint: Major Depressive Disorder - Current and Future Players

Summary

GlobalData has released its pharma report, “PharmaPoint: Major Depressive Disorder - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Major Depressive Disorder Market. The report identifies and analyses the key companies shaping and driving the global Major Depressive Disorder market. The report provides insight into the competitive Major Depressive Disorder landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData’s team of industry experts.

Scope

- Investigation of current and future market competition for Major Depressive Disorder.
- Competitor assessment
- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
- Strategic assessment of Major Depressive Disorder sector through market impact analysis, future market scenario and company analysis

Reasons to buy

- Gain a high level view of the trends shaping and driving Major Depressive Disorder market.
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
- What’s the next big thing in the global Major Depressive Disorder market landscape? Identify, understand and capitalize

Table Of Contents

1 Table of Contents

2 Introduction 11
2.1 Catalyst 11
2.2 Related Reports 11
2.3 Upcoming Related Reports 13
3 Market Outlook 14
3.1 Global 14
3.1.1 Forecast 14
3.1.2 Drivers and Barriers - Global Issues 18
4 Current and Future Players 20
4.1 Overview 20
4.2 Trends in Corporate Strategy 23
4.3 Company Profiles 24
4.3.1 Lundbeck 24
4.3.2 Forest Laboratories (Actavis) 28
4.3.3 Eli Lilly 31
4.3.4 Pfizer 32
4.3.5 Otsuka Pharmaceutical 34
4.3.6 AstraZeneca 37
4.3.7 Takeda Pharmaceutical 38
4.3.8 Alkermes 40
4.3.9 Euthymics Bioscience 42
4.3.10 Naurex 44
4.3.11 e-Therapeutics 46
5 Appendix 49
5.1 Bibliography 49
5.2 Abbreviations 50
5.3 Methodology 52
5.4 Forecasting Methodology 52
5.4.1 Diagnosed MDD Patients 52
5.4.2 Percent of Drug-Treated Patients 52
5.4.3 General Pricing Assumptions 53
5.4.4 Generic Erosion 54
5.5 Physicians and Specialists Included in this Study 54
5.6 About the Authors 56
5.6.1 Analyst 56
5.6.2 Therapy Area Directors 56
5.6.3 Global Head of Healthcare 57
5.7 About GlobalData 58
5.8 Disclaimer 58


1.1
List of Tables


Table 1: Global Sales Forecasts ($) for MDD, 2013-2023 16
Table 2: MDD Market - Drivers and Barriers, 2013-2023 18
Table 3: Key Companies in the MDD Market in the 7MM and Australia, 2013 22
Table 4: Lundbeck’s MDD Portfolio Assessment, 2013 26
Table 5: Forest (Actavis)’s MDD Portfolio Assessment, 2013 29
Table 6: Eli Lilly’s MDD Portfolio Assessment, 2013 31
Table 7: Pfizer’s MDD Portfolio Assessment, 2013 33
Table 8: Otsuka’s MDD Portfolio Assessment, 2013 35
Table 9: AstraZeneca’s MDD Portfolio Assessment, 2013 37
Table 10: Takeda’s MDD Portfolio Assessment, 2013 39
Table 11: Alkermes’s MDD Portfolio Assessment, 2013 41
Table 12: Euthymics Bioscience’s MDD Portfolio Assessment, 2013 43
Table 13: Naurex’s MDD Portfolio Assessment, 2013 45
Table 14: e-Therapeutics’s MDD Portfolio Assessment, 2013 47
Table 15: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country 55

1.2
List of Figures

Figure 1: Global Sales for MDD by Region, 2013-2023 17
Figure 2: Company Portfolio Gap Analysis in MDD, 2013-2023 23
Figure 3: Lundbeck SWOT Analysis in MDD, 2013-2023 27
Figure 4: Forest (Actavis) SWOT Analysis in MDD, 2013-2023 30
Figure 5: Eli Lilly SWOT Analysis in MDD, 2013-2023 32
Figure 6: Pfizer SWOT Analysis in MDD, 2013-2023 34
Figure 7: Otsuka SWOT Analysis in MDD, 2013-2023 36
Figure 8: AstraZeneca SWOT Analysis in MDD, 2013-2023 38
Figure 9: Takeda SWOT Analysis in MDD, 2013-2023 40
Figure 10: Alkermes SWOT Analysis in MDD, 2013-2023 42
Figure 11: Euthymics Bioscience SWOT Analysis in MDD, 2013-2023 44
Figure 12: Naurex SWOT Analysis in MDD, 2013-2023 46
Figure 13: e-Therapeutics SWOT Analysis in MDD, 2013-2023 48

Companies Mentioned
Lundbeck
Forest Laboratories (Actavis)
Eli Lilly
Pfizer
Otsuka Pharmaceutical
AstraZeneca
Takeda Pharmaceutical
Alkermes
Euthymics Bioscience
Naurex
e-Therapeutics

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Analysis of the Global Infectious Disease Diagnostics Market

Analysis of the Global Infectious Disease Diagnostics Market

  • $ 10 000
  • Industry report
  • September 2014
  • by Frost & Sullivan

Molecular Methods Present Significant Opportunities This deliverable provides research and analysis of the global infectious disease diagnostics market. It includes an in-depth analysis of revenue forecast ...

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018

  • $ 7 995
  • Industry report
  • June 2014
  • by Global Data

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018 Summary Chronic lymphocytic leukemia (CLL), the most common form of adult leukemia, is caused by the uncontrolled ...

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation

  • $ 6 995
  • Industry report
  • July 2014
  • by GBI Research

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation Summary Exceptionally Large and Innovative Pipeline The breast cancer pipeline is the largest in the pharmaceutical ...

Bcc Research Bitopertin Forecast

August 2014 $ 5 500

6 Companies

Company Profiles

SYNTHES Inc.

Switzerland

Biosense Webster Inc.

United States

Synthes Inc.

United States

Johnson and Johnson

United States

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.